Skye Bioscience (SKYE) M&A announcement summary

Deal rationale and strategic fit

• The merger creates Fibrx Therapeutics, a Nasdaq-listed pure-play fibrosis company focused on advancing a differentiated pipeline of anti-fibrotic therapies, primarily targeting unmet needs in fibrostenotic Crohn's disease.

• The combined entity leverages Redx's clinical-stage assets, discovery expertise, and experienced management team, aiming for multiple value inflection points.

• Strategic decisions include discontinuing Skye's CBeyond trial and redeploying capital in response to a changed competitive landscape.

• The merger allows Skye shareholders to participate in future value creation from Redx's pipeline while preserving upside from Skye's legacy asset via contingent value rights.

• The strategic goal is to become a leader in anti-fibrotic therapies, with a robust pipeline including DDR and ROCK2 inhibitors.

Financial terms and conditions

• The deal includes aggregate financings of approximately $125 million, comprising PIPE, Series A, and equity line facilities, providing a cash runway into 2029.

• Pro-forma ownership: pre-merger Skye holders ~5.38%, Redx holders up to 59.75%, and new investors up to 48.45%, subject to adjustments.

• Skye shareholders receive a contingent value right to 90% of net cash proceeds from any monetization of nimacimab within 12 months post-closing.

• Redx shareholders receive CVRs for 100% of net proceeds from certain legacy assets over 15 years.

• Pro forma valuation of the combined company is $264.5 million.

Synergies and expected cost savings

• The merger consolidates leadership and R&D expertise, with Redx's executive team leading Fibrx, expected to drive efficient development of the fibrosis portfolio.

• Combined cash is expected to fund operations into 2029, supporting advancement through key clinical milestones, including RXC008 Phase 2 topline data in H2 2028.